Director and 10% Owner Invests $15M in Private Placement
QTTB has more than doubled off its 52-week low of $1.345.
Summary
A director and 10% owner, linked to OrbiMed, invested $15 million in Q32 Bio's recent private placement, signaling strong confidence and providing substantial capital.
Key Events · Ownership and Investor Activity · QTTB
-
Significant Insider Investment
Xu Diyong, a Director and 10% owner (associated with OrbiMed), purchased $15 million worth of common stock.
-
Part of Private Placement
This investment was made at $8.00 per share as part of the $55 million private placement announced on May 27, 2026.
-
Substantial Capital Infusion
The $15 million investment represents approximately 7.6% of the company's current market capitalization, providing a significant capital boost.
Analysis · QTTB · Life Sciences
Xu Diyong, a Director and 10% owner associated with OrbiMed, made a substantial $15 million investment in Q32 Bio's common stock. This purchase was part of the $55 million private placement announced on May 27th, providing significant capital to the company. The investment, representing over 7% of the company's market capitalization, demonstrates strong conviction from a key institutional investor and director.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.4% of the 1170 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTTB was trading at $11.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $197.7M. The 52-week trading range was $1.35 to $13.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.